Literature DB >> 2053063

Choriocarcinoma of the septum pellucidum: case report.

S Koyama1, T Tsubokawa, Y Katayama, H Hirota.   

Abstract

A case of choriocarcinoma of the septum pellucidum is presented. The patient, a 6-year-old boy, demonstrated high levels of human chorionic gonadotropin in his urine, serum, and cerebrospinal fluid, and precocious puberty. The physical conditions and laboratory data returned to normal after surgical removal of the tumor, whole brain irradiation, and chemotherapy. Currently, there is no evidence of recurrence at 5 months after surgery.

Entities:  

Mesh:

Year:  1991        PMID: 2053063     DOI: 10.1016/0090-3019(91)90184-b

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  5 in total

1.  Primary intracranial choriocarcinoma: MR imaging findings.

Authors:  X-F Lv; Y-W Qiu; X-L Zhang; L-J Han; S-J Qiu; W Xiong; G Wen; Y-Z Zhang; J Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-08       Impact factor: 3.825

2.  Mixed germ cell tumors in septum pellucidum after radiochemotherapy of suprasellar germinoma: de novo metachronous or recurrent neoplasms?

Authors:  Ki Seong Eom; Jong Moon Kim; Tae Young Kim
Journal:  Childs Nerv Syst       Date:  2008-06-17       Impact factor: 1.475

Review 3.  Long-term survival in malignant intracranial germ-cell tumors: a report of two cases and a review of the literature.

Authors:  N Sakai; H Yamada; T Andoh; Y Nishimura; S Niikawa
Journal:  Childs Nerv Syst       Date:  1993-11       Impact factor: 1.475

4.  Endoscope-assisted microsurgery for tumors of the septum pellucidum: surgical considerations and benefits of the method in the treatment of four serial cases.

Authors:  M Fratzoglou; A R Leite dos Santos; I Gawish; A Perneczky
Journal:  Neurosurg Rev       Date:  2004-05-12       Impact factor: 3.042

Review 5.  Prognostic factors and therapeutic problems of primary intracranial choriocarcinoma/germ-cell tumors with high levels of HCG.

Authors:  Jun Shinoda; Noboru Sakai; Hirohito Yano; Tatsuaki Hattori; Akio Ohkuma; Heima Sakaguchi
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.